Search

Your search keyword '"Moelans, Cathy B."' showing total 416 results
Start Over Author "Moelans, Cathy B."
416 results on '"Moelans, Cathy B."'

1. A YAP-centered mechanotransduction loop drives collective breast cancer cell invasion

Author

Khalil, Antoine A., Smits, Daan, Haughton, Peter D., Koorman, Thijs, Jansen, Karin A., Verhagen, Mathijs P., van der Net, Mirjam, van Zwieten, Kitty, Enserink, Lotte, Jansen, Lisa, El-Gammal, Abdelrahman G., Visser, Daan, Pasolli, Milena, Tak, Max, Westland, Denise, van Diest, Paul J., Moelans, Cathy B., Roukens, M. Guy, Tavares, Sandra, Fortier, Anne-Marie, Park, Morag, Fodde, Riccardo, Gloerich, Martijn, Zwartkruis, Fried. J. T., Derksen, Patrick WB., and de Rooij, Johan

Published
2024
Full Text
View/download PDF

5. The Diagnostic Value of microRNA Expression Analysis in Detecting Intraductal Papillomas in Patients with Pathological Nipple Discharge

Author

MS CGO, Pathologie patiënten zorg, Cancer, Heelkunde Opleiding, Pathologie, Pathologie Groep Van Diest, Makineli, Seher, Vriens, Menno R., Witkamp, Arjen J., van Diest, Paul J., Moelans, Cathy B., MS CGO, Pathologie patiënten zorg, Cancer, Heelkunde Opleiding, Pathologie, Pathologie Groep Van Diest, Makineli, Seher, Vriens, Menno R., Witkamp, Arjen J., van Diest, Paul J., and Moelans, Cathy B.

Published
2024

9. Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1–NDRG1 deregulation

Author

Mayayo‐Peralta, Isabel, primary, Debets, Donna O., additional, Prekovic, Stefan, additional, Schuurman, Karianne, additional, Beerthuijzen, Suzanne, additional, Almekinders, Mathilde, additional, Sanders, Joyce, additional, Moelans, Cathy B., additional, Saleiro, Sandra, additional, Wesseling, Jelle, additional, van Diest, Paul J., additional, Henrique, Rui, additional, Jerónimo, Carmen, additional, Altelaar, Maarten, additional, and Zwart, Wilbert, additional

Published
2023
Full Text
View/download PDF

12. Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1–NDRG1 deregulation.

Author

Mayayo‐Peralta, Isabel, Debets, Donna O., Prekovic, Stefan, Schuurman, Karianne, Beerthuijzen, Suzanne, Almekinders, Mathilde, Sanders, Joyce, Moelans, Cathy B., Saleiro, Sandra, Wesseling, Jelle, van Diest, Paul J., Henrique, Rui, Jerónimo, Carmen, Altelaar, Maarten, and Zwart, Wilbert

Abstract

Breast cancer (BCa) is a highly heterogeneous disease, with hormone receptor status being a key factor in patient prognostication and treatment decision‐making. The majority of primary tumours are positive for oestrogen receptor alpha (ERα), which plays a key role in tumorigenesis and disease progression, and represents the major target for treatment of BCa. However, around one‐third of patients with ERα‐positive BCa relapse and progress into the metastatic stage, with 20% of metastatic cases characterised by loss of ERα expression after endocrine treatment, known as ERα‐conversion. It remains unclear whether ERα‐converted cancers are biologically similar to bona fide ERα‐negative disease and which signalling cascades compensate for ERα loss and drive tumour progression. To better understand the biological changes that occur in metastatic BCa upon ERα loss, we performed (phospho)proteomics analysis of 47 malignant pleural effusions derived from 37 BCa patients, comparing ERα‐positive, ERα‐converted and ERα‐negative cases. Our data revealed that the loss of ERα‐dependency in this metastatic site leads to only a partial switch to an ERα‐negative molecular phenotype, with preservation of a luminal‐like proteomic landscape. Furthermore, we found evidence for decreased activity of several key kinases, including serum/glucocorticoid regulated kinase 1 (SGK1), in ERα‐converted metastases. Loss of SGK1 substrate phosphorylation may compensate for the loss of ERα‐dependency in advanced disease and exposes a potential therapeutic vulnerability that may be exploited in treating these patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. A tumor cell specific Zona Pellucida glycoprotein 3 RNA transcript encodes an intracellular cancer antigen

Author

Pathologie Groep Van Diest, Cancer, Pathologie, Schultz, Iman J, Zimmerman, Yvette, Moelans, Cathy B, Chrusciel, Marcin, Krijgh, Jan, van Diest, Paul J, Huhtaniemi, Ilpo T, Coelingh Bennink, Herjan J T, Pathologie Groep Van Diest, Cancer, Pathologie, Schultz, Iman J, Zimmerman, Yvette, Moelans, Cathy B, Chrusciel, Marcin, Krijgh, Jan, van Diest, Paul J, Huhtaniemi, Ilpo T, and Coelingh Bennink, Herjan J T

Published
2023

19. Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions

Author

Joosten, Stacey E.P., Gregoricchio, Sebastian, Stelloo, Suzan, Yapıcı, Elif, Huang, Chia-Chi Flora, Yavuz, Kerim, Donaldson Collier, Maria, Morova, Tunc, Altintas, Umut Berkay, Kim, Yongsoo, Canisius, Sander, Moelans, Cathy B., van Diest, Paul J., Korkmaz, Gozde, Lack, Nathan A., Vermeulen, Michiel, Linn, Sabine C., and Zwart, Wilbert

Abstract

Estrogen Receptor 1 (ESR1; also known as ERα, encoded by ESR1gene) is the main driver and prime drug target in luminal breast cancer. ESR1 chromatin binding is extensively studied in cell lines and a limited number of human tumors, using consensi of peaks shared among samples. However, little is known about inter-tumor heterogeneity of ESR1 chromatin action, along with its biological implications. Here, we use a large set of ESR1 ChIP-seq data from 70 ESR1+breast cancers to explore inter-patient heterogeneity in ESR1 DNA binding to reveal a striking inter-tumor heterogeneity of ESR1 action. Of note, commonly shared ESR1 sites show the highest estrogen-driven enhancer activity and are most engaged in long-range chromatin interactions. In addition, the most commonly shared ESR1-occupied enhancers are enriched for breast cancer risk SNP loci. We experimentally confirm SNVs to impact chromatin binding potential for ESR1 and its pioneer factor FOXA1. Finally, in the TCGA breast cancer cohort, we can confirm these variations to associate with differences in expression for the target gene. Cumulatively, we reveal a natural hierarchy of ESR1–chromatin interactions in breast cancers within a highly heterogeneous inter-tumor ESR1 landscape, with the most common shared regions being most active and affected by germline functional risk SNPs for breast cancer development.

Published
2024
Full Text
View/download PDF

25. Patient-centered research:how do women tolerate nipple fluid aspiration as a potential screening tool for breast cancer?

Author

Patuleia, Susana I. S., Moelans, Cathy B., Koopman, Jasmijn, van Steenhoven, Julia E. C., van Dalen, Thijs, van der Pol, Carmen C., Jager, Agnes, Ausems, Margreet G. E. M., van Diest, Paul J., van der Wall, Elsken, Suijkerbuijk, Karijn P. M., Patuleia, Susana I. S., Moelans, Cathy B., Koopman, Jasmijn, van Steenhoven, Julia E. C., van Dalen, Thijs, van der Pol, Carmen C., Jager, Agnes, Ausems, Margreet G. E. M., van Diest, Paul J., van der Wall, Elsken, and Suijkerbuijk, Karijn P. M.

Abstract

Background: Nipple fluid aspiration (NFA) is a technique to acquire nipple aspirate fluid (NAF), which is considered a rich source of breast-specific biomarkers. Originating directly from the mammary ducts, this liquid biopsy can offer insight into the process of carcinogenesis at its earliest stage and therefore could be of added value to the current imaging-based breast cancer screening tools. With that in mind, it is necessary to know how well NFA is tolerated. Aim: To evaluate the participants’ tolerability of NFA compared to breast imaging screening methods and blood draws. Materials and methods: Three cohorts of women underwent NFA: healthy women (n = 190), women diagnosed with breast cancer (n = 137) and women at high risk of developing breast cancer (n = 48). A 0–10 discomfort score of NFA, mammography, breast MRI and blood draws, was filled in at the study visits, which took place once or annually. Results: The median discomfort rate of NFA was 1, which was significantly lower than the median discomfort of mammography and breast MRI (5 and 3, respectively, p < 0.001), but significantly higher than median discomfort for blood draws (0, p < 0.001). The great majority of women would undergo the procedure again (98%) and recommend it to others (97%). Conclusion: This study shows that NFA was well tolerated by healthy women, women diagnosed with breast cancer and high-risk women. This makes NFA a feasible method to pursue as a potential future breast cancer early detection tool, based on resident biomarkers. Trial registration: NL41845.041.12, NL57343.041.16 and NL11690.041.06 in trialregister.nl.

Published
2022

26. Patient-centered research: how do women tolerate nipple fluid aspiration as a potential screening tool for breast cancer?

Author

Pathologie Groep Van Diest, Cancer, MS CGO, Genetica Klinische Genetica, Pathologie, Speerpunt Cancer, MS Medische Oncologie, Infection & Immunity, Patuleia, Susana I S, Moelans, Cathy B, Koopman, Jasmijn, van Steenhoven, Julia E C, van Dalen, Thijs, van der Pol, Carmen C, Jager, Agnes, Ausems, Margreet G E M, van Diest, Paul J, van der Wall, Elsken, Suijkerbuijk, Karijn P M, Pathologie Groep Van Diest, Cancer, MS CGO, Genetica Klinische Genetica, Pathologie, Speerpunt Cancer, MS Medische Oncologie, Infection & Immunity, Patuleia, Susana I S, Moelans, Cathy B, Koopman, Jasmijn, van Steenhoven, Julia E C, van Dalen, Thijs, van der Pol, Carmen C, Jager, Agnes, Ausems, Margreet G E M, van Diest, Paul J, van der Wall, Elsken, and Suijkerbuijk, Karijn P M

Published
2022

27. Analytical Validation of a Novel 6-Gene Signature for Prediction of Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative, Early-Stage Breast Cancer

Author

Pathologie Groep Van Diest, Cancer, Pathologie, Loughman, Tony, Barron, Stephen, Wang, Chan-Ju Angel, Dynoodt, Peter, Fender, Bozena, Lopez-Ruiz, Cesar, Stapleton, Sharon, Fabre, Aurelie, Quinn, Cecily, Nodin, Bjorn, Jirström, Karin, Razmara, Fatemeh, O'Grady, Anthony, Baird, Anne-Marie, Gray, Steven G, Freixo, Ana, Moelans, Cathy B, van Diest, Paul J, Duffy, Michael J, O'Leary, Desmond, Crown, John, Bracken, Adrian P, Gallagher, William M, Pathologie Groep Van Diest, Cancer, Pathologie, Loughman, Tony, Barron, Stephen, Wang, Chan-Ju Angel, Dynoodt, Peter, Fender, Bozena, Lopez-Ruiz, Cesar, Stapleton, Sharon, Fabre, Aurelie, Quinn, Cecily, Nodin, Bjorn, Jirström, Karin, Razmara, Fatemeh, O'Grady, Anthony, Baird, Anne-Marie, Gray, Steven G, Freixo, Ana, Moelans, Cathy B, van Diest, Paul J, Duffy, Michael J, O'Leary, Desmond, Crown, John, Bracken, Adrian P, and Gallagher, William M

Published
2022

28. Elevated miR-29c-5p Expression in Nipple Aspirate Fluid Is Associated with Extremely High Mammographic Breast Density

Author

Pathologie Groep Van Diest, Cancer, Epi Kanker Team A, Speerpunt Cancer, Pathologie, JC onderzoeksprogramma Kanker, Vissers, Tessa A C M, Piek, Leonie, Patuleia, Susana I S, Duinmeijer, Aafke J, Bakker, Marije F, van der Wall, Elsken, van Diest, Paul J, van Gils, Carla H, Moelans, Cathy B, Pathologie Groep Van Diest, Cancer, Epi Kanker Team A, Speerpunt Cancer, Pathologie, JC onderzoeksprogramma Kanker, Vissers, Tessa A C M, Piek, Leonie, Patuleia, Susana I S, Duinmeijer, Aafke J, Bakker, Marije F, van der Wall, Elsken, van Diest, Paul J, van Gils, Carla H, and Moelans, Cathy B

Published
2022

33. Patient-centered research: how do women tolerate nipple fluid aspiration as a potential screening tool for breast cancer?

Author

Patuleia, Susana I.S., primary, Moelans, Cathy B., additional, Koopman, Jasmijn, additional, Steenhoven, Julia E.C. van, additional, Dalen, Thijs van, additional, Pol, Carmen C. van der, additional, Jager, Agnes, additional, Ausems, Margreet G.E.M., additional, Diest, Paul J. van, additional, Wall, Elsken van der, additional, and Suijkerbuijk, Karijn P.M., additional

Published
2022
Full Text
View/download PDF

34. Additional file 4 of Patient-centered research: how do women tolerate nipple fluid aspiration as a potential screening tool for breast cancer?

Author

Patuleia, Susana I. S., Moelans, Cathy B., Koopman, Jasmijn, van Steenhoven, Julia E. C., van Dalen, Thijs, van der Pol, Carmen C., Jager, Agnes, Ausems, Margreet G. E. M., van Diest, Paul J., van der Wall, Elsken, and Suijkerbuijk, Karijn P. M.

Abstract

Additional file 4. Supplementary File 2. Discomfort questionnaire

Published
2022
Full Text
View/download PDF

35. Nipple Aspirate Fluid at a Glance

Author

Patuleia, Susana I. S., primary, Suijkerbuijk, Karijn P. M., additional, van der Wall, Elsken, additional, van Diest, Paul J., additional, and Moelans, Cathy B., additional

Published
2021
Full Text
View/download PDF

40. The changing microRNA landscape by color and cloudiness:a cautionary tale for nipple aspirate fluid biomarker analysis

Author

Patuleia, Susana I.S., van der Wall, Elsken, van Gils, Carla H., Bakker, Marije F., Jager, Agnes, Voorhorst-Ogink, Marleen M., van Diest, Paul J., Moelans, Cathy B., Patuleia, Susana I.S., van der Wall, Elsken, van Gils, Carla H., Bakker, Marije F., Jager, Agnes, Voorhorst-Ogink, Marleen M., van Diest, Paul J., and Moelans, Cathy B.

Abstract

Purpose: Investigation of nipple aspirate fluid (NAF)-based microRNAs (miRNAs) as a potential screening tool for women at increased risk of developing breast cancer is the scope of our research. While aiming to identify discriminating NAF-miRNAs between women with different mammographic densities, we were confronted with an unexpected confounder: NAF sample appearance. Here we report and alert for the impact of NAF color and cloudiness on miRNA assessment. Methods: Seven classes of NAF colors coupled with cloudiness appearance were established. Using 173 NAF samples from 154 healthy women (19 samples were bilaterally collected), the expression of 14 target and 2 candidate endogenous control (EC) miRNAs was investigated using Taqman Advanced miRNA assays to identify significant differential expression patterns between color-cloudiness classes. Inter- and intra-individual variation of miRNA expression was analyzed using the coefficient of variation (CV). Results: We found that between the seven NAF classes, fold change miRNA expression differences ranged between 2.4 and 19.6 depending on the interrogated miRNA. Clear NAF samples exhibited higher miRNA expression levels compared to cloudy NAF samples with fold change differences ranging between 1.1 and 6.2. Inter-individual and intra-individual miRNA expression was fairly stable (CV < 15 %), but nevertheless impacted by NAF sample appearance. Within NAF classes, inter-individual variation was largest for green samples (CV 6-15 %) and smallest for bloody samples (CV 2-6 %). Conclusions: Our data indicate that NAF color and cloudiness influence miRNA expression and should, therefore, be systematically registered using an objective color classification system. Given that sample appearance is an inherent feature of NAF, these variables should be statistically controlled for in multivariate data analyses. This cautionary note and recommendations could be of value beyond the field of NAF-miRNAs, given that variability

Published
2021

41. Nipple Aspirate Fluid at a Glance

Author

Cancer, Pathologie Groep Van Diest, MS Medische Oncologie, Infection & Immunity, Speerpunt Cancer, Pathologie, Patuleia, Susana I S, Suijkerbuijk, Karijn P M, van der Wall, Elsken, van Diest, Paul J, Moelans, Cathy B, Cancer, Pathologie Groep Van Diest, MS Medische Oncologie, Infection & Immunity, Speerpunt Cancer, Pathologie, Patuleia, Susana I S, Suijkerbuijk, Karijn P M, van der Wall, Elsken, van Diest, Paul J, and Moelans, Cathy B

Published
2021

42. The changing microRNA landscape by color and cloudiness: a cautionary tale for nipple aspirate fluid biomarker analysis

Author

Pathologie Groep Van Diest, Cancer, Speerpunt Cancer, Epi Kanker Team A, JC onderzoeksprogramma Kanker, Pathologie, Patuleia, Susana I S, van der Wall, Elsken, van Gils, Carla H, Bakker, Marije F, Jager, Agnes, Voorhorst-Ogink, Marleen M, van Diest, Paul J, Moelans, Cathy B, Pathologie Groep Van Diest, Cancer, Speerpunt Cancer, Epi Kanker Team A, JC onderzoeksprogramma Kanker, Pathologie, Patuleia, Susana I S, van der Wall, Elsken, van Gils, Carla H, Bakker, Marije F, Jager, Agnes, Voorhorst-Ogink, Marleen M, van Diest, Paul J, and Moelans, Cathy B

Published
2021

43. Cytoplasmic DDX3 as prognosticator in male breast cancer

Author

Pathologie Groep Van Diest, Cancer, MS Radiotherapie, Trialbureau Beeld, MS MOD, Speerpunt Cancer, MS CGO, Regenerative Medicine and Stem Cells, JC onderzoeksprogramma Kanker, Pathologie, van der Pol, Carmen C., Moelans, Cathy B., Manson, Quirine F., Batenburg, Marilot C.T., van der Wall, Elsken, Borel Rinkes, Inne, Verkooijen, Lenny, Raman, Venu, van Diest, Paul J., Pathologie Groep Van Diest, Cancer, MS Radiotherapie, Trialbureau Beeld, MS MOD, Speerpunt Cancer, MS CGO, Regenerative Medicine and Stem Cells, JC onderzoeksprogramma Kanker, Pathologie, van der Pol, Carmen C., Moelans, Cathy B., Manson, Quirine F., Batenburg, Marilot C.T., van der Wall, Elsken, Borel Rinkes, Inne, Verkooijen, Lenny, Raman, Venu, and van Diest, Paul J.

Published
2021

44. Heterogeneity in signaling pathway activity within primary and between primary and metastatic breast cancer

Author

Pathologie Algemene Pat.zorg, Pathologie Groep Van Diest, Cancer, Pathologie, Inda, Márcia A., van Swinderen, Paul, van Brussel, Anne, Moelans, Cathy B., Verhaegh, Wim, van Zon, Hans, Den Biezen, Eveline, Bikker, Jan Willem, van Diest, Paul J., van de Stolpe, Anja, Pathologie Algemene Pat.zorg, Pathologie Groep Van Diest, Cancer, Pathologie, Inda, Márcia A., van Swinderen, Paul, van Brussel, Anne, Moelans, Cathy B., Verhaegh, Wim, van Zon, Hans, Den Biezen, Eveline, Bikker, Jan Willem, van Diest, Paul J., and van de Stolpe, Anja

Published
2021

45. Lessons Learned from Setting Up a Prospective, Longitudinal, Multicenter Study with Women at High Risk for Breast Cancer

Author

Pathologie Groep Van Diest, Cancer, Genetica Klinische Genetica, Epi Kanker Team A, JC onderzoeksprogramma Kanker, Pathologie, Speerpunt Cancer, Patuleia, Susana I S, Hagenaars, Sophie C, Moelans, Cathy B, Ausems, Margreet G E M, van Gils, Carla H, Tollenaar, Rob A E M, van Diest, Paul J, Mesker, Wilma E, van der Wall, Elsken, Pathologie Groep Van Diest, Cancer, Genetica Klinische Genetica, Epi Kanker Team A, JC onderzoeksprogramma Kanker, Pathologie, Speerpunt Cancer, Patuleia, Susana I S, Hagenaars, Sophie C, Moelans, Cathy B, Ausems, Margreet G E M, van Gils, Carla H, Tollenaar, Rob A E M, van Diest, Paul J, Mesker, Wilma E, and van der Wall, Elsken

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results